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OBJECTIVES The goal of this study was to determine the prognostic significance of estimated creatinine
clearance (CrCl) in relation to 6-min walk distance in ambulatory patients with congestive
heart failure (HF).
BACKGROUND Although measurement of renal function is integral to the management of chronic congestive
HF, its prognostic implications are not well described and have not been formally evaluated
relative to measures of functional capacity.
METHODS We analyzed outcomes of the 585 participants of the 6-min walk substudy of the Digitalis
Investigation Group (DIG) trial. The CrCl was estimated using the Cockcroft-Gault
equation. Predictors of all-cause mortality were identified using semiparametric Cox
proportional hazards regression and completely parametric hazard analyses.
RESULTS Most subjects (85%) were New York Heart Association functional class II and III. Mean age
was 65 (12) years and mean ejection fraction (EF) 35% (13%). There were 153 (26%)
deaths during a median of 2.6 years of follow-up. Mortality by increasing quartiles of
estimated CrCl was 37% (18 to 48 ml/min), 29% (47 to 64 ml/min), 18% (64 to 86 ml/min),
and 21% (86 to 194 ml/min) with corresponding hazard ratios (HRs) relative to the top
quartile of 2.1 (95% confidence interval [CI], 1.4 to 3.3), 1.6 (95% CI, 1.0 to 2.5), and 0.9
(95% CI, 0.5 to 1.5), respectively. In Cox regression analyses, independent predictors of
mortality were estimated CrCl (adjusted HR [quartile 1:quartile 4] 1.5; 95% CI, 1.1 to 2.1),
6-min walk distance 262 m [adjusted HR, 1.63; 95% CI, 1.12 to 2.27]), EF, recent
hospitalization for worsening HF, and need for diuretic treatment. Parametric (hazard)
analysis confirmed consistent effects of estimated CrCl on mortality in several subgroups
including that of patients with EF 45%.
CONCLUSIONS In ambulatory patients with congestive HF, estimated CrCl predicts all-cause mortality
independently of established prognostic variables. (J Am Coll Cardiol 2002;40:1106–13)
© 2002 by the American College of Cardiology Foundation
Measurement of renal function is integral to the manage-
ment of chronic congestive cardiac failure and influences
clinical decision-making (1). Moreover, data from the
Studies Of Left Ventricular Dysfunction (SOLVD) registry
have suggested that renal function may provide independent
prognostic information both in symptomatic and asymp-
tomatic heart failure (HF) (2). However, studies systemat-
ically evaluating the prognostic significance of renal function
in cardiac failure are surprisingly few, and the degree to
which this variable has been evaluated in relation to tradi-
tional prognostic markers including exercise tolerance is
limited.
The 6-min walk test is an objective measure of exercise
capacity that can be obtained in a range of settings and is an
independent predictor of mortality in cardiac failure (3–5).
This test was employed in a substudy of the Digitalis
Investigation Group (DIG) trial, a large-scale multicenter
study designed to evaluate the effect of digoxin on morbidity
and mortality in patients with HF in sinus rhythm (6). The
aim of this study was to determine the prognostic utility of
estimated creatinine clearance (CrCl) relative to traditional
prognostic markers, including exercise capacity, in patients
participating in the exercise substudy of the DIG trial.
METHODS
Patients. Full details of the DIG trial have been published
elsewhere (6). Briefly, for the main trial (n  6,800) eligible
patients had HF (based on current or past clinical symptoms
or signs and/or on X-ray evidence of pulmonary congestion
[7] and an ejection fraction [EF] 45% as determined by
echocardiography, radionuclide scanning, or ventriculogra-
phy). Patients with HF and EF 45% were enrolled in an
ancillary trial (n  998). In 39 of 302 participating centers,
585 patients were enrolled in a 6-min walk test substudy
designed to measure the effect of treatment on functional
capacity. Inclusion criteria were as for the overall trial.
Follow-up for up to five years (median 3.2 years) was
available on all 7,788 patients who participated in the DIG
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trial including the 585 patients in the exercise substudy
(median follow-up 2.6 years). For this analysis only all-cause
mortality was considered as an end point, as, unlike “car-
diovascular mortality,” it is clinically relevant, wholly objec-
tive, and unbiased (8,9).
The Cleveland Clinic Foundation Institutional Review
Board approved analyses based on the publicly available
DIG data set.
Calculation of CrCl. All patients had serum creatinine
recorded at baseline. Estimated CrCl was calculated for
each patient using the Cockcroft-Gault equation: CrCl
(men) ([140 age in years]·weight in kg) / (72·creatinine
in mg/dl) (10). For women the above was multiplied by
0.85.
6-min walk test. The 6-min walk test was performed using
standard methods (11). Distance walked at 3 min and 6
min, total duration of walk if 6 min, whether there were
any breaks, and reasons for stopping were recorded. Other
baseline clinical data on all participants were recorded as
documented previously (6). These included EF as measured
either by echocardiography (29%), radionuclide angiogra-
phy (67%), or ventriculography (4%) within six months
before enrollment, provided there had been no intercurrent
cardiac event.
Statistical analysis. Patients were ranked according to
CrCl, and comparisons of baseline variables between groups
were performed using the Wilcoxon rank-sum test for
continuous variables and the chi-square test for categorical
variables. All analyses were performed with two-sided p
values. Survival according to CrCl, 6-min walk distance,
and other potential predictors of mortality was assessed
using Kaplan-Meier curves (12) and Cox proportional
hazards (13) with transformations of all continuous variables
tested. Optimal proportional hazard models were identified
using the Akaike Information Criterion (14). The Cox
proportional hazards model was also used to test for
interactions between creatinine quartiles and other baseline
variables. The proportional hazards assumption was con-
firmed by examination of Schoenfeld residuals. In addition,
a model incorporating serum creatinine rather than CrCl
was tested, with age and gender entered separately, but this
had a chi-square inferior to that incorporating CrCl.
Model validation was carried out by means of bootstrap
resampling (15,16). A total of 1,000 resampling analyses
were performed for variable selection using p  0.10 for
model entry and p  0.05 for model retention. Those
variables that were retained in at least half the models were
considered in 1,000 fixed variable resamplings.
In addition, a completely parametric survival analysis was
carried out to resolve the number of hazard phases, identify
the form of the equation for each phase, and estimate the
parameters that characterized the distribution of times until
death (17). Only one hazard phase, which followed an
exponential distribution, was found. Using the HAZARD
procedure, with stepwise variable entry, a multivariable risk
factor model was generated with a value of p  0.05
criterion for retention of variables in the final model.
Graphical displays of survival according to CrCl under
varying conditions of concomitant variables are also shown
using the proc HAZPRED and proc HAZPLOT func-
tions. All analyses were performed using SAS version 8.1
software (SAS Inc., Cary, North Carolina). The HAZ-
ARD, HAZPRED, and HAZPLOT macros, and a discus-
sion of parametric survival analysis can be found at www.
clevelandclinic.org/heartcenter/hazard.
RESULTS
Baseline characteristics. Baseline characteristics of pa-
tients in the exercise substudy were similar to those of the
main trial except for the presence of more individuals with
EF45% in the exercising group than the main group (20%
vs. 12%, p  0.0001) with consequent lower follow-up
mortality (26% vs. 34%, p  0.0001). Nonetheless, mortal-
ity in the exercise group was substantial and amounted to
153 deaths over the follow-up period. Mean baseline serum
creatinine was similar in both groups. Results hereafter refer
only to the group participating in the exercise substudy.
Baseline variables in CrCl subgroups. Table 1 lists base-
line variables according to strata of CrCl. Patients in the
lower two quartiles were significantly older than those in the
highest quartile, had lower body mass index (BMI), shorter
6-min walk distances, and a higher proportion of female
patients. More patients in the lower two quartiles had a
recent hospitalization for HF, were in New York Heart
Association functional classes III and IV, or required regular
diuretic therapy. There was no difference in EF between the
ranks even when patients with EF 45% were excluded
from analysis. History of previous myocardial infarction,
diabetes mellitus, and use of angiotensin-converting enzyme
(ACE) inhibitors did not differ between the groups.
CrCl, functional capacity, and survival. Survival accord-
ing to quartiles of CrCl is shown in Figure 1A. Survival was
significantly reduced in patients with CrCl in the lower two
quartiles. Figure 1B shows survival according to quartiles of
6-min walk distance. Survival was significantly impaired in
patients in the lowest quartile (walk distance 262 m).
Stratified analyses. To evaluate consistency of effect of
CrCl on survival, mortality according to CrCl was analyzed
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BMI  body mass index
CI  confidence interval
CrCl  creatinine clearance
DIG  Digitalis Investigation Group
EF  ejection fraction
HF  heart failure
HR  hazard ratio
SOLVD  Studies Of Left Ventricular Dysfunction
VO2  oxygen consumption
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in prespecified subgroups. The effect of estimated CrCl was
generally consistent across all subgroups inspected (Table
2). However, there was evidence of a weak interaction
between CrCl and history of previous myocardial infarction,
with a high mortality in patients with no history of
myocardial infarction irrespective of CrCl, and between
CrCl and walk distance, with low CrCl having less of an
adverse effect in individuals with very poor functional
capacity.
Multivariable survival analyses. Preliminary Cox propor-
tional hazards analysis was performed with consideration of
the following variables: lowest quartile of 6-min walk
distance, age, gender, BMI, EF, resting heart rate, previous
myocardial infarction, diabetes mellitus, systolic blood pres-
sure, log CrCl, use of diuretics, cardiothoracic ratio, recent
hospitalization for worsening heart failure, presence of a
third heart sound, and the presence of auscultatory rales.
Log CrCl was found to perform better than untransformed
CrCl in proportional hazards modeling. No other variable
transformation improved the models. Only log CrCl, 6-min
walk distance, use of diuretics, recent hospitalization for
HF, and EF emerged as independent predictors of mortal-
ity.
To create a final model, these 14 variables were entered
into 1,000 models based on 1,000 bootstrap resamplings
(Table 3). Only five variables entered models more than
50% of the time: 6-min walk distance, EF, diuretic use,
hospitalization for worsening HF, and log CrCl. Log CrCl
and EF entered the highest number of models. Repeating
the resampling with categorization of continuous variables
such as age did not affect the results. Similarly, performing
the analysis only for patients with EF 45% did not affect
the results. These five variables were subsequently consid-
ered in 1,000 fixed variable resamplings for calculation of
hazard ratios (Table 3).
Parametric analyses. As expected, parametric analyses
yielded the same independent predictors of death as did
proportional hazards modeling. There was no interaction
Table 1. Baseline Variable Distribution According to Quartiles of Creatinine Clearance
1 (7.8–47.1)
n  145
2 (47.1–63.8)
n  146
3 (63.9–85.8)
n  146
4 (86.0–193.6)
n  146 p Value
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
6-min walk distance 272 (124) 307 (118) 336 (119) 359 (119) 0.0001
Serum potassium level 4.4 (0.4) 4.3 (0.4) 4.3 (0.4) 4.2 (0.4) 0.04
Time since diagnosis of heart failure (months) 17 (27) 25 (32) 24 (38) 26 (35) 0.0004
Age 75 (11) 68 (8) 63 (8) 54 (10) 0.0001
Body mass index 24 (4) 26 (4) 29 (5) 32 (7) 0.0001
Systolic blood pressure 129 (22) 127 (22) 128 (21) 129 (23) 0.9
Diastolic blood pressure 72 (11) 74 (11) 76 (12) 79 (13) 0.0001
Heart rate 76 (13) 77 (12) 77 (12) 77 (14) 0.8
Cardiothoracic ratio 0.6 (0.1) 0.5 (0.1) 0.5 (0.1) 0.5 (0.1) 0.0005
EF* 29 (9) 29 (10) 30 (9) 30 (8) 0.88
Serum creatinine (mg) 1.6 (0.5) 1.3 (0.2) 1.2 (0.2) 1.0 (0.2) 0.0001
n (%) n (%) n (%) n (%) p (Chi2)
Congestion on chest X-ray 17 (11) 15 (10) 14 (10) 13 (9) 0.87
Ejection fraction 25 38 (26) 42 (28) 38 (26) 34 (23) 0.77
Male gender 85 (59) 110 (75) 116 (79) 120 (82) 0.0001
Diabetes mellitus 38 (26) 39 (27) 42 (29) 42 (29) 0.94
Previous myocardial infarction 94 (65) 95 (65) 95 (65) 92 (63) 0.98
Non-white race 14 (10) 22 (15) 22 (15) 23 (16) 0.4
Recent hospitalization for worsening CHF 56 (39) 53 (36) 34 (23) 39 (27) 0.01
Edema 27 (19) 17 (12) 31 (21) 39 (37) 0.0122
Elevated JVP 14 (10) 13 (9) 16 (11) 17 (12) 0.86
Rales 23 (16) 18 (12) 23 (16) 21 (14) 0.81
S3 30 (21) 28 (19) 26 (18) 28 (19) 0.94
Exertional dyspnea 111 (77) 105 (72) 100 (68) 115 (79) 0.18
Rest dyspnea 13 (9) 21 (14) 27 (18) 42 (29) 0.0001
NYHA  3 59 (41) 45 (31) 27 (25) 45 (31) 0.04
ACE inhibitor 122 (84) 133 (91) 128 (88) 130 (89) 0.32
Digoxin† 60 (41) 60 (41) 57 (39) 46 (32) 0.26
Diuretic 122 (84) 115 (78) 105 (72) 94 (64) 0.0007
Potassium-sparing diuretic 12 (8) 10 (7) 6 (4) 9 (6) 0.53
Nitrates 2 (1) 7 (5) 52 (36) 56 (38) 0.96
Hydralazine 54 (37) 53 (36) 2 (1) 3 (2) 0.18
Other vasodilator 19 (13) 26 (18) 31 (21) 31 (21) 0.23
Randomized to digoxin 82 (57) 75 (51) 69 (47) 74 (51) 0.46
Death during follow-up 54 (37) 43 (29) 26 (18) 30 (21) 0.0005
*Excludes ejection fraction (EF) 45% group; †on digoxin before randomization.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; JVP  jugular venous pressure; NYHA  New York Heart association.
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Figure 1. Kaplan-Meier curve of survival by quartiles of baseline creatinine clearance (A) and quartiles of baseline 6-min walk distance (B).
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noted between CrCl and 6-min walk distance. Plots de-
scribing four-year survival according to CrCl for different
degrees of exercise limitation and left ventricular dysfunc-
tion are shown in Figures 2 and 3. In all circumstances there
was a continuous decline in survival with falling CrCl, with
sharper declines observed as CrCl fell below 40 to 50
ml/min. To determine whether CrCl had similar prognostic
implications in the subgroup with HF and EF 45%, a
second hazard analysis was performed with EF dichoto-
mized at the 45% level. There were comparable effects of
estimated CrCl on survival in both groups. No interaction
was found.
DISCUSSION
Renal function in congestive HF. Few studies have sys-
tematically explored the prognostic utility of renal function
in cardiac failure. In the Prospective Randomized Milrinone
Survival Evaluation (PROMISE) study involving 1,088
patients, a serum creatinine level 1.3 mg/dl was associated
with a trend towards increased all-cause mortality (18).
Subsequent smaller studies have also suggested that serum
creatinine predicts all-cause or cardiovascular mortality (19–
21). However, analysis of serum creatinine (rather than
CrCl) is potentially problematic because of the confounding
effects of age, gender, and BMI. Accordingly, in an analysis
from the SOLVD prevention and treatment studies (n 
6,887), CrCl (Cockcroft-Gault) 60 ml/min was shown
independently to predict pump-failure deaths and the com-
bined end point of death or hospitalization (2). In the
present study the relationship between CrCl and prognosis
was confirmed over a wider range of creatinine levels
because in the SOLVD trial a creatinine level2 mg/dl was
an exclusion criterion, and among patients whose therapy
more closely approximated to current HF management
because the majority (93%) was on ACE inhibitors. Fur-
thermore, this study demonstrated a continuous relationship
between CrCl and survival. As is clear from the hazard
plots, the probability of survival was reduced by even minor
Table 2. Survival According to Creatinine Clearance (“High”  Ranks 3 and 4; “Low”  Ranks 1 and 2) in Selected Subgroups
High Estimated CrCl
(63.9–193.6)
Low Estimated CrCl
(7.8–63.8)
Hazard Ratio
(95% CI) p (Cox)
Interactions
Number of Deaths (%) Number of Deaths (%) p Value
Gender M 46/237 (19) 70/195 (36) 2.06 (1.42–2.99) 0.0001 0.66
F 10/57 (18) 27/96 (28) 1.75 (0.85–3.62) 0.13
Cachectic (BMI  23) No 53/271 (20) 61/205 (30) 1.64 (1.14–2.37) 0.008 0.14
Yes 3/23 (13) 36/86 (42) 3.71 (1.14–12.05) 0.03
Age  65 No 37/204 (18) 20/61 (33) 2.06 (1.19–3.54) 0.01 0.34
Yes 19/90 (21) 77/230 (33) 1.70 (1.03–2.80) 0.04
ACE inhibitor therapy No 4/36 (11) 16/36 (44) 4.85 (1.62–14.56) 0.005 0.11
Yes 52/258 (20) 81/255 (32) 1.72 (1.21–2.43) 0.002
Diabetes mellitus No 40/209 (19) 75/214 (35) 2.01 (1.37–2.95) 0.0004 0.62
Yes 16/85 (19) 22/77 (29) 1.73 (0.91–3.30) 0.10
Previous MI No 29/106 (27) 33/102 (32) 1.25 (0.76–2.06) 0.38 0.02
Yes 27/188 (14) 64/189 (33) 2.65 (1.69–4.16)  0.0001
Ejection fraction  25 No 42/259 (16) 73/243 (30) 1.73 (1.15–2.61) 0.008 0.39
Yes 14/35 (40) 24/48 (50) 2.27 (1.30–3.97) 0.004
NYHA class  3 No 28/212 (13) 49/187 (26) 2.20 (1.38–3.49) 0.0009 0.27
Yes 28/82 (34) 48/104 (46) 1.44 (0.90–2.29) 0.13
White No 44/248 (18) 86/255 (34) 2.12 (1.48–3.05)  0.0001 0.18
Non-white Yes 12/46 (26) 11/36 (31) 1.25 (0.55–2.84) 0.59
Short 6-min walk distance* No 42/251 (17) 56/186 (30) 1.99 (1.33–2.96) 0.0008 0.04
Yes 14/43 (33) 41/105 (40) 1.25 (0.68–2.29) 0.48
*Lowest quartile (263 m).
ACE  angiotensin-converting enzyme; BMI  body mass index; CI  confidence interval; CrCl  creatinine clearance; MI  myocardial infarction; NYHA  New York
Heart Association.
Table 3. Variables Associated With Mortality in
Multivariable Models
Variables
Number of Bootstrap
Models Entered
(Out of 1,000)
Hazard
Ratio 95% CI
Ejection fraction 934 0.97 0.96–0.98
Log (estimated CrCl) 931 0.50 0.34–0.77
Recent hospitalization for
worsening CHF
677 1.57 1.12–2.18
Diuretic treatment 653 1.92 1.22–3.57
Short 6-min walk
distance*
704 1.63 1.12–2.27
Previous MI 408 — —
Body mass index 399 — —
S3 328 — —
Rales 327 — —
Gender 324 — —
Age 184 — —
Cardiothoracic ratio 160 — —
Diabetes mellitus 149 — —
Diastolic blood pressure 62 — —
*Lowest quartile (263 m) vs. remaining quartiles.
CHF  congestive heart failure; CI  confidence interval; CrCl  creatinine
clearance; MI  myocardial infarction.
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reductions in CrCl, levels at which the serum creatinine
might still be normal.
Renal function and exercise capacity in HF. In addition,
the present study incorporated an objective measure of
exercise capacity. While this study confirmed that 6-min
walk distance independently predicts mortality in HF pa-
tients, of greater interest is the finding that CrCl predicted
survival independently of measured functional capacity and
Figure 2. Hazard plot demonstrating survival according to creatinine clearance in patients with and without abnormal exercise tolerance with ejection
fraction (EF), history of hospitalization, and diuretic use specified. Note that similar plots can be constructed for any specified EF, history of hospitalization,
and diuretic use. WD6 6-min walk distance. A value of262 m corresponded to the lowest quartile. Bold lines probability of survival; broken lines
95% confidence intervals.
Figure 3. Hazard plot demonstrating survival according to creatinine clearance in patients with different degrees of left ventricular dysfunction, with 6-min
walk distance, history of hospitalization, and diuretic use specified. Bold lines  probability of survival; broken lines  95% confidence intervals.
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that low CrCl was associated with a reduced probability of
survival irrespective of effort tolerance. Indeed, CrCl may be
a particularly useful marker in individuals with less severely
impaired functional capacity, in whom the prognosis may be
unclear. Similarly, we demonstrated a consistent effect of
CrCl on survival in patients with different degrees of
ventricular dysfunction, including patients with HF and
normal systolic function, with potential implications for its
use as a prognostic marker in individuals with less severe
degrees of left ventricular dysfunction.
Impact of renal function on natural history of HF
potential mechanisms. The mechanisms by which im-
paired renal function exerts an adverse prognostic effect
remain to be established. As proposed previously (2), renal
dysfunction may have a causative role in the progression of
cardiac failure, through subtle alterations in the ability to
control volume status and/or compromised clearance of
cardiac toxins. An active role for renal dysfunction in this
regard is supported by published reports of resolution of
secondary ventricular dysfunction after renal transplantation
in patients with primary renal insufficiency (22–26).
Study limitations. The Cockcroft-Gault formula is based
on ideal rather than actual body weight. Because many
patients in the DIG trial had clinical congestion, baseline
recorded weights may have exceeded ideal body weights.
Furthermore, the formula performs less well in subgroups
including diabetics and at the extremes of age and body size
(27).
With respect to the generalizability of these findings, the
DIG trial had no upper age limit, and its participants may
more closely resemble the general population than partici-
pants in more complex studies. Nonetheless, the mean age
of 64 years is lower than in practice (28), and caution must
be exercised in extrapolating these findings to older patients
with HF. Furthermore, this trial did not include patients
with atrial fibrillation, who account for approximately 20%
of patients with HF in major HF studies (29,30).
Due to the limited dataset, the prognostic utility of peak
oxygen consumption (VO2) (or, indeed, of potential newer
markers such as natriuretic peptides) could not be evaluated.
The 6-min walk test is less established as a prognostic tool
than peak VO2, may be subject to greater degrees of
variability, likely measures submaximal rather than maximal
exercise capacity, and correlates only modestly with peak
VO2 (5,31–34). In one study 6-min walk distance was not
prognostic if peak VO2 was included in the model (34).
However, for the majority of patients with HF, the walk test
may be a more practical, albeit cruder, prognostic functional
test.
Implications. Assessment of prognosis is central to the
delivery of patient care and is a basis on which important
therapeutic decisions are made, including referral for cardiac
transplantation. The use, for prognostic purposes, of a
variable that is universally recorded in patients with HF is
inherently attractive. Recently, Aaronson et al. (35) have
developed predictive models incorporating several com-
monly measured prognostic variables, not including CrCl (a
dichotomous variable “renal disease [moderate or severe]”
was recorded but did not enter the final models) (35). In
view of the importance of renal function in the assessment
and management of HF, and in light of emerging evidence
of its prognostic importance, CrCl may be an appropriate
variable for inclusion in future prognostic models.
Conclusions. In ambulatory patients with chronic conges-
tive cardiac failure, CrCl predicts all-cause mortality inde-
pendently of established clinical, structural, and functional
prognostic variables.
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